On October 2, Axinn partner Chad Landmon spoke on a panel entitled, "180-Day Exclusivity: What is Past is Prologue" at the GRx+Biosims Conference  held October 2-4 in North Bethesda, MD. 

As the critical role that 180-day exclusivity plays in accelerating patient access to generic medicines continues to be misunderstood by policymakers, journalists, and other stakeholders, panelists explored subjects such as the complex history of 180-day exclusivity, and the potential impact of recent reform proposals.

Click here for more information.